KKR expects to see increasing restructuring and recapitalization opportunities in China as the country’s role in the global economy adjusts, resulting in a sustained period of slower growth.
Henry McVey, the firm's head of global macro and asset allocation - and whose views are therefore not an indicator of investment strategy - identified China restructuring as one of five macro arbitrages...
Chinese gene therapy specialist Exegenesis Bio has received $20 million in Series B funding led by Legend Capital. It will be used to support clinical development of the company’s drug portfolio.
Alibaba Group has led a $300 million round for Chinese electric vehicle (EV) manufacturer Xpeng Motors. It comes barely two weeks after the company closed an extended Series C round of $500 million.
EDBI, the investment arm of Singapore’s Economic Development Board, has invested in Vesta, a US-based fraud and payment technology start-up with ambitions to expand into Asia.
Hana Financial has invested KRW100 billion ($85 million) in a portfolio of Korean waste to energy (WTE) projects controlled by Global Infrastructure Partners (GIP).